This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Imovax
- Generic Name
- Rabies virus inactivated antigen, B
- DrugBank Accession Number
- DB10062
- Background
Inactivated rabies virus antigen B is a component of rabies vaccines used for pre- and post-exposure prophylaxis against rabies.1
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Rabies virus strain PM-1503-3M antigen (propiolactone inactivated)
- Rabies virus vaccine wistar strain PM-1503-3M (human)
Pharmacology
- Indication
Inactivated rabies virus antigen B is indicated for pre- and post-exposure prophylaxis against rabies.1
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Anakinra. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit). 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Imovax Rabies Injection 2.5 [iU]/1mL Intramuscular Sanofi Pasteur Inc. 2019-10-25 Not applicable US 
Imovax Rabies Injection 2.5 [iU]/1mL Intramuscular Sanofi Pasteur Inc. 1980-06-09 2021-12-07 US Imovax Rabies Rabies Vaccine Inactivated (dco) Powder, for solution 2.5 unit / vial Intramuscular Sanofi Pasteur Limited 1999-08-13 Not applicable Canada 
Categories
- ATC Codes
- J06AA06 — Rabies serum
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- C4HQF74XMW
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Diarrhea / Fever / Influenza-like Illness / Upper Respiratory Disease 1 4 Completed Prevention Rabies Vaccine Adverse Reaction 1 4 Completed Treatment Rabies 1 4 Unknown Status Diagnostic Primary Immunodeficiencies (PID) 1 3 Completed Prevention Rabies (Healthy Volunteers) 2 3 Completed Prevention Rabies / Rabies Virus 1 3 Completed Treatment Rabies 1 3 Recruiting Prevention Rabies (Healthy Volunteers) 1 2 Completed Prevention Dengue Dengue Fever Dengue Hemorrhagic Fever / Dengue Diseases / Dengue Fever / Dengue Virus 1 2 Completed Prevention Plasmodium Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intramuscular 2.5 [iU]/1mL Powder, for solution Intramuscular 2.5 unit / vial Injection 9 IU/ml Injection, powder, for solution 2.5 iu/mL Injection 2.5 mcg/0.5ml Powder 2.5 mcg/0.5ml Injection, powder, for suspension Intramuscular Injection, powder, for suspension Intramuscular 2.5 IU Injection, powder, for suspension Intramuscular 2.5 iu/0.5ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at November 30, 2015 21:23 / Updated at May 28, 2022 06:24